Following the spectacular crash and burn of the Symplicity HTN-3 trial at the American College of Cardiology two weeks ago, the future of renal denervation (RDN)-- the once highly promising catheter ...
Medtronic plc (NYSE:MDT) is one of the top stock picks in Ken Griffin’s portfolio. On August 25, analysts at TD Cowen reiterated a ‘Buy’ rating on the stock and a $106 price target. The bullish stance ...
REDWOOD CITY, Calif. — OPENLANE chief executive officer Daniel Farrar looked to quell any apprehension from recovery agencies about the online auction company's recent acquisition of Recovery Database ...
Medtronic plc MDT recently announced long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial. The SPYRAL HTN-ON MED is a global, randomized, sham-controlled study investigating the ...
DeepQure Inc., a pioneering medical device startup, is revolutionizing the treatment of resistant hypertension with its innovative extravascular (laparoscopic approach) renal denervation (RDN) device, ...
Interv Cardiol. 2014;6(1):57-69. Appropriate patient selection is critical, and should be made by a hypertension expert in a specialized center. Optimal medical therapy is an important prerequisite, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results